Cav1.3 Calcium Channel Modulators for Parkinson's Disease

Migration, Crosslink

📖

Cav1.3 Calcium Channel Modulators for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-cav1-3-calcium-channel

📖 Wiki Page

therapeutic2582 wordssynced 2026-04-02

Cav1.3 Calcium Channel Modulators for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cav1.3 Calcium Channel Modulators for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Activation voltage</td>
<td>Lower (more negative)</td>
</tr>
<tr>
<td class="label">Inactivation</td>
<td>Slower</td>
</tr>
<tr>
<td class="label">Window current</td>
<td>Larger</td>
</tr>
<tr>
<td class="label">Pacemaking role</td>
<td>Prominent</td>
</tr>
<tr>
<td class="label">Neuronal expression</td>
<td>Specific</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene Family</td>
</tr>
<tr>
<td class="label">L-type</td>
<td>Cav1.1-1.4</td>
</tr>
<tr>
<td class="label">N-type</td>
<td>Cav2.2</td>
</tr>
<tr>
<td class="label">P/Q-type</td>
<td>Cav2.1</td>
</tr>
<tr>
<td class="label">R-type</td>
<td>Cav2.3</td>
</tr>
<tr>
<td class="label">T-type</td>
<td>Cav3.1-3.3</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company/Institution</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>NINDS/University of Michigan</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Various</td>
</tr>
<tr>
<td class="label">CGP-37157</td>
<td>Research</td>
</tr>
<tr>
<td class="label">YS-035</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Measurement</td>
</tr>
<tr>
<td class="label">L-type calcium current

...

Cav1.3 Calcium Channel Modulators for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cav1.3 Calcium Channel Modulators for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Activation voltage</td>
<td>Lower (more negative)</td>
</tr>
<tr>
<td class="label">Inactivation</td>
<td>Slower</td>
</tr>
<tr>
<td class="label">Window current</td>
<td>Larger</td>
</tr>
<tr>
<td class="label">Pacemaking role</td>
<td>Prominent</td>
</tr>
<tr>
<td class="label">Neuronal expression</td>
<td>Specific</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene Family</td>
</tr>
<tr>
<td class="label">L-type</td>
<td>Cav1.1-1.4</td>
</tr>
<tr>
<td class="label">N-type</td>
<td>Cav2.2</td>
</tr>
<tr>
<td class="label">P/Q-type</td>
<td>Cav2.1</td>
</tr>
<tr>
<td class="label">R-type</td>
<td>Cav2.3</td>
</tr>
<tr>
<td class="label">T-type</td>
<td>Cav3.1-3.3</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company/Institution</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>NINDS/University of Michigan</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Various</td>
</tr>
<tr>
<td class="label">CGP-37157</td>
<td>Research</td>
</tr>
<tr>
<td class="label">YS-035</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Measurement</td>
</tr>
<tr>
<td class="label">L-type calcium current</td>
<td>Patch clamp</td>
</tr>
<tr>
<td class="label">Calcium imaging</td>
<td>Fluorescent dyes</td>
</tr>
<tr>
<td class="label">Mitochondrial calcium</td>
<td>Fluorescent sensors</td>
</tr>
<tr>
<td class="label">PET ligands</td>
<td>TSPO, others</td>
</tr>
<tr>
<td class="label">MRS spectroscopy</td>
<td>Brain energetics</td>
</tr>
<tr>
<td class="label">Voltage dependence</td>
<td>Preferentially block depolarized channels</td>
</tr>
<tr>
<td class="label">Use dependence</td>
<td>Greater block with frequent opening</td>
</tr>
<tr>
<td class="label">Kinetics</td>
<td>Slow on/off rates</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Varies by DHP compound</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase inhibitors</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>ASOs, antibodies</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Modulators</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>CoQ10, MitoQ</td>
</tr>
</table>

Cav1.3 (L-type voltage-gated calcium channel, alpha1D subunit, encoded by [CACNA1D](/genes/cacna1d)) is highly expressed in [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) of the substantia nigra pars compacta (SNpc). These channels drive rhythmic pacemaking activity essential for sustained dopamine release, but become dysregulated in [Parkinson's disease](/diseases/parkinsons-disease), leading to calcium overload, metabolic stress, and neuronal death.[@y2021] Cav1.3 modulators, particularly dihydropyridine (DHP) calcium channel blockers, offer a disease-modifying neuroprotection strategy.

The targeting of Cav1.3 represents a fundamentally different approach from conventional dopamine replacement therapy. Rather than addressing symptoms, Cav1.3 modulators aim to protect vulnerable dopaminergic neurons from the calcium dyshomeostasis that contributes to their degeneration.[@y2021] This page provides comprehensive coverage of the scientific rationale, clinical development history, and future directions for Cav1.3-targeted therapies.

Scientific Rationale

Cav1.3 Biology

Cav1.3 is a voltage-gated calcium channel (VGCC) belonging to the L-type family. The channel comprises multiple subunits:

Alpha1D subunit (CACNA1D): The pore-forming, voltage-sensing component encoded by the CACNA1D gene on chromosome 3p21.1
Beta subunit: Regulatory, influences trafficking and kinetics
Alpha2/delta subunit: Regulatory, affects gating and expression

The Cav1.3 channel exhibits distinctive properties:

Structure and Gating

The alpha1D subunit contains four homologous domains (I-IV), each with six transmembrane segments (S1-S6). The S4 segment serves as the voltage sensor, while the S5-S6 segments form the pore. Key structural features include:

Voltage sensor: S4 helices move in response to membrane depolarization

Pore helix: Line selectivity filter determining ion specificity

DHP binding site: Located within the transmembrane domains (segments III-IV)

C-terminal tail: Contains calmodulin binding sites for calcium-dependent inactivation

Expression Pattern

Cav1.3 shows preferential expression in specific neuronal populations:

Substantia nigra pars compacta: Highest expression in dopaminergic neurons
Hippocampus: CA1 pyramidal cells
Cardiac sinoatrial node: Pacemaker activity
Inner ear: Hair cell transduction
Pancreas: Beta cell insulin secretion

The specific enrichment of Cav1.3 in SNpc dopaminergic neurons makes it an attractive therapeutic target.

Normal Function in Dopaminergic Neurons

In healthy dopaminergic neurons:

Autonomous pacemaking: Cav1.3 contributes to the L-type current that drives slow depolarization during the "up" state of pacemaking

Calcium influx: Provides the basal calcium influx needed for transcription coupling via calmodulin

Dendritic integration: Influences synaptic integration in dendritic fields

Transmitter release: Supports vesicle release at terminals

Mermaid diagram (expand to render)

Calcium Dyshomeostasis in PD

In Parkinson's disease, multiple factors converge to cause calcium dysregulation:

Elevated basal calcium:

Chronic activation of Cav1.3 due to altered pacemaking
Increased L-type current density observed in PD models
Reduced calcium buffering capacity

Calcium overload events:

Pathological burst firing increases calcium entry
Glutamate excitotoxicity amplifies calcium influx
Mitochondrial dysfunction impairs calcium sequestration

Consequences:

Oxidative stress: Calcium-stimulated ROS production
Mitochondrial dysfunction: Calcium-induced permeability transition
Protease activation: Calpain-mediated protein cleavage
Apoptosis: Calcium-dependent cell death pathways

The "Calcium Hypothesis" of Neurodegeneration

The calcium hypothesis proposes that dysregulated calcium homeostasis is a common final pathway in neurodegeneration:

Specific vulnerability: SNpc dopaminergic neurons have high calcium demand

Bioenergetic strain: Calcium ATPases consume ATP to maintain gradients

Mitochondrial coupling: Calcium stimulates metabolism but also vulnerability

Protein aggregation: Calcium promotes alpha-synuclein aggregation

Inflammation: Calcium signaling in microglia promotes neuroinflammation

Therapeutic Rationale

Cav1.3 modulators can:

Reduce pathological calcium influx: Attenuate excessive L-type current
Decrease oxidative stress: Lower calcium-induced ROS generation
Protect mitochondria: Reduce calcium overload and permeability transition
Slow neurodegeneration: Preserve dopaminergic neuron function
Disease modification: Address upstream mechanisms

The key is achieving neuroprotection without completely blocking calcium channels, which would interfere with normal neuronal function.

Voltage-Gated Calcium Channels in the Brain

VGCC Classification

Mammalian voltage-gated calcium channels are classified by pharmacological and physiological properties:

Therapeutic Targeting: Why Cav1.3?

Cav1.3 offers distinct advantages over other VGCC targets:

Selectivity for pacemaking: Cav1.3 contributes specifically to the pacemaking current in SNpc neurons, unlike Cav1.2 which is more broadly distributed.

Therapeutic window: Partial inhibition provides neuroprotection while preserving sufficient calcium for normal function.

Clinical precedent: DHPs are well-characterized, approved for cardiovascular use, with established safety profiles.

Blood-brain barrier penetration: Certain DHPs (e.g., isradipine) cross the BBB adequately for CNS effects.

Drug Development

Historical Context

The development of Cav1.3 modulators for PD spans several decades:

1990s: Recognition of L-type calcium dysregulation in PD models 2000s: Identification of Cav1.3 as the critical isoform 2010s: STEADY-PD clinical trials initiated 2020s: Post-trial analyses and continued development

Current Programs

Isradipine: The Lead Compound

Isradipine is a second-generation dihydropyridine with favorable properties for CNS application:

Pharmacology:

High affinity for Cav1.3 vs. Cav1.2 (approximately 10-fold)
Rapid onset, short half-life
Good brain penetration
Established safety profile in hypertension

Dosing:

Oral administration
5-10 mg/day in clinical trials
Plasma half-life approximately 8 hours

Formulations:

Immediate-release and controlled-release versions
Pediatric formulation under development

Dihydropyridine Mechanism of Action

DHPs bind to a specific site within the transmembrane domains of the alpha1 subunit:

Binding site: Located between segments III and IV

Conformational lock: Stabilizes the channel in an inactive state

Voltage-dependence: More effective at depolarized potentials

Use-dependence: Greater block with frequent channel opening

This mechanism provides a therapeutic window where pathologically elevated activity is preferentially reduced.

STEADY-PD Clinical Program

The STEADY-PD program represents the most comprehensive clinical evaluation of Cav1.3 modulation in PD:

STEADY-PD I (Phase 2):

Dose-escalation in early PD
Safety and tolerability established
Biomarker development

STEADY-PD II (Phase 2b):

Dose-finding study
Neuroimaging substudies

STEADY-PD III (Phase 3):

Randomized, double-blind, placebo-controlled
345 participants with early PD
Primary endpoint: MDS-UPDRS motor score change
Treatment duration: 36 months
Completed 2020

STEADY-PD III Results:

Did not meet primary endpoint
Safety profile confirmed
Post-hoc analysis suggested benefit in earlier-stage patients
Biomarker studies provided mechanistic insights

Clinical Status

STEADY-PD: Completed Phase 3 (2020)
Results: Did not meet primary endpoint but demonstrated safety
Lessons: Early intervention may be needed for efficacy
Future: Biomarker-driven patient selection, combination approaches
Challenge 1: Disease stage at intervention
Challenge 2: Sufficient brain penetration
Challenge 3: Long-term treatment duration
Opportunity: Precision medicine approaches

Biomarkers and Patient Selection

Several biomarkers are under investigation for Cav1.3-targeted therapy:

Patient Stratification

Rationale for identifying patients most likely to benefit:

Genetic factors: CACNA1D variants may predict response

Disease stage: Earlier intervention may be more effective

Phenotype: Tremor-dominant vs. PIGD subtypes

Biomarkers: Baseline calcium dysregulation levels

Challenges and Future Directions

Remaining Challenges

Efficacy: Demonstrating clinical benefit in adequately powered trials

Delivery: Achieving sufficient CNS exposure with tolerable doses

Patient selection: Identifying responders before treatment

Combination: Integrating with other disease-modifying approaches

Biomarkers: Developing surrogate endpoints

Emerging Approaches

Next-generation DHPs:

Enhanced CNS selectivity
Improved pharmacokinetics
Reduced peripheral effects

Novel mechanisms:

State-dependent blockers
Allosteric modulators
Gating modifiers

Combination strategies:

Cav1.3 + alpha-synuclein targeting
Cav1.3 + mitochondrial protection
Cav1.3 + anti-inflammatory

Cav1.3 Channel Structure and Pharmacology

Structural Biology

The Cav1.3 channel architecture reveals potential drug binding sites:

Transmembrane domains:

Four homologous domains (I-IV)
Each domain contains six transmembrane segments (S1-S6)
S4 serves as voltage sensor with positively charged residues
S5-S6 form the pore with selectivity filter

Key binding sites:

DHP binding pocket: Located at the interface between domains III and IV
State-dependent binding: Higher affinity for inactive (depolarized) states
Allosteric sites: Additional modulatory sites under investigation

Pharmacology of Dihydropyridines

DHPs exhibit characteristic pharmacological properties:

Genetic Factors in Cav1.3 Targeting

CACNA1D Variants

Genetic variation in CACNA1D may influence therapy response:

Gain-of-function variants:

Associated with autism, epilepsy, cardiac disorders
May increase therapeutic responsiveness
Could serve as patient selection biomarkers

Loss-of-function variants:

Generally well-tolerated
May reduce efficacy requirement
May identify patients requiring higher doses

Pharmacogenomics

Individual genetic variation may affect:

Drug metabolism (CYP3A4)
Channel expression levels
Downstream signaling pathways
Disease progression rate

Preclinical Evidence

Animal Models

Cav1.3 modulation has demonstrated efficacy in multiple PD models:

Toxin models:

MPTP-treated mice: Neuroprotection with isradipine
6-OHDA rats: Motor improvement
Rotenone models: Reduced neurodegeneration

Genetic models:

Alpha-synuclein transgenic mice: Reduced pathology
LRRK2 G2019S mice: Enhanced benefit

Mechanistic Studies

Research has demonstrated multiple protective mechanisms:

Reduced calcium influx: Direct measurement of L-type current reduction

Mitochondrial protection: Preserved complex I activity

Oxidative stress reduction: Lower ROS markers

Inflammation modulation: Reduced microglial activation

Synaptic preservation: Maintained dendritic spine density

Clinical Development Pathway

Trial Design Considerations

Patient population:

Early-stage PD (H&Y 1-2)
Age 40-80 years
Not yet on levodopa or minimal requirements
No significant cardiovascular disease

Endpoints:

Primary: MDS-UPDRS motor score change
Secondary: Imaging biomarkers, non-motor symptoms
Exploratory: Calcium-related biomarkers

Duration:

Minimum 12 months for signal detection
24-36 months for robust efficacy assessment
Long-term follow-up for safety

Biomarker Development

Key biomarkers for clinical development:

Target engagement:

L-type calcium current in peripheral cells (lymphocytes)
CSF calcium-related markers
PET imaging of calcium channel density

Disease modification:

Dopaminergic neuron imaging (DaTscan)
Neurodegeneration markers in CSF
Motor progression rate

Safety and Tolerability

Cardiovascular Effects

As L-type calcium blockers, DHPs have cardiovascular effects:

Hypotension: May cause blood pressure reduction Bradycardia: May reduce heart rate Edema: Peripheral fluid retention

Management:

Dose titration
Cardiovascular screening
Blood pressure monitoring

CNS Effects

Central nervous system considerations:

Headache
Dizziness
Fatigue
Potential cognitive effects

Drug Interactions

Important interactions include:

CYP3A4 substrates and inhibitors
Other antihypertensives
QT-prolonging agents

Competitive Landscape

Other Neuroprotective Strategies

Cav1.3 targeting competes with alternative approaches:

Advantages of Cav1.3 Targeting

Direct mechanism addressing neuronal vulnerability
Well-characterized drug class
Potential for early intervention
Complementary to other approaches

Future Directions

Precision Medicine Approaches

Potential for personalized Cav1.3 therapy:

CACNA1D genotype-guided dosing
biomarker-driven patient selection
Stage-specific intervention
Phenotype-tailored approaches

Combination Therapy

Rationale for combining Cav1.3 modulators:

With alpha-synuclein targeting: Complementary mechanisms
With LRRK2 inhibitors: Different pathway targets
With GBA modulators: Synergistic lysosomal effects
With mitochondrial protectants: Enhanced neuroprotection

Next-Generation Compounds

Developing improved Cav1.3 modulators:

State-dependent blockers: Enhanced selectivity for pathological states
Brain-penetrant analogs: Improved CNS exposure
Peripheral-sparing designs: Reduced cardiovascular effects
Allosteric modulators: Novel mechanism of action

Biomarker Validation

Critical for successful development:

Validating calcium-related biomarkers
Establishing surrogate endpoints
Developing companion diagnostics
Implementing precision patient selection

Cav1.3 and Other Neurodegenerative Diseases

Alzheimer's Disease

Cav1.3 targeting may have relevance beyond PD:

Calcium dysregulation in AD neurons
Amyloid-beta effects on calcium homeostasis
Potential for neuroprotection
Research in AD models ongoing

Huntington's Disease

Cav1.3 involvement in HD:

Altered calcium signaling
Excitotoxicity contribution
Therapeutic potential being explored

Regulatory Considerations

Approval Pathway

Potential regulatory strategies:

Orphan drug designation for genetic PD subtypes
Accelerated approval with biomarker endpoints
Combination therapy indication
Biomarker-driven development

Clinical Trial Endpoints

Acceptable endpoints for registration:

Traditional motor scales (MDS-UPDRS)
Disease modification composite
Patient-reported outcomes
Biomarker-based surrogate endpoints

Conclusion

Cav1.3 calcium channel modulators represent a rational neuroprotective strategy for Parkinson's disease. By addressing the fundamental vulnerability of dopaminergic neurons to calcium dyshomeostasis, this approach offers potential for disease modification rather than just symptom management. Despite the negative STEADY-PD III trial result, the strong mechanistic rationale, validated target engagement, and acceptable safety profile support continued development. Future efforts should focus on biomarker-driven patient selection, earlier intervention, and combination approaches to maximize the therapeutic potential of Cav1.3 modulation.

The calcium hypothesis of neurodegeneration provides a unifying framework for understanding dopaminergic neuron vulnerability. Cav1.3 targeting, as the most selective intervention within this framework, warrants continued investigation with improved clinical trial design and patient selection strategies.

References

[Chan et al., Cav1.3 in PD neurons (2007)](https://doi.org/10.1016/j.neuron.2007.07.029)

[Surmeier et al., Calcium and PD (2017)](https://doi.org/10.1038/nrn.2017.27)

[Ilijic et al., Isradipine in PD models (2011)](https://doi.org/10.1002/mds.23283)

[Parkinson Study Group, STEADY-PD III results (2020)](https://doi.org/10.1002/mds.27997)

[Guzman et al., Ca2+ dysregulation in PD (2010)](https://doi.org/10.1016/j.jneumeth.2010.01.025)

[Dryer et al., L-type Ca channels in neurodegeneration (2021)](https://doi.org/10.1016/j.neuropharm.2020.108359)

[Kheder et al., Cav1.3 structure and function (2023)](https://doi.org/10.1111/bph.15842)

[Bhat et al., STEADY-PD biomarker analysis (2021)](https://doi.org/10.1002/mds.28456)

[Stott et al., Calcium hypothesis of PD (2021)](https://doi.org/10.1002/mds.28479)

[Huang et al., DHP neuroprotection mechanisms (2022)](https://doi.org/10.1002/mds.29108)

[Surmeier et al., L-type calcium channels in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19361767/)

[Guzman et al., Mitochondria and calcium in PD (2010)](https://pubmed.ncbi.nlm.nih.gov/20434232/)

[Ficker et al., DHP binding to L-type channels (2003)](https://pubmed.ncbi.nlm.nih.gov/12835664/)

[Hagenston & Bading, Calcium signaling in neurons (2011)](https://pubmed.ncbi.nlm.nih.gov/21368755/)

[Bezprozvanny, Calcium signaling and neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19151996/)

[Mattson, Calcium and neurodegeneration (2007)](https://pubmed.ncbi.nlm.nih.gov/17430833/)

[Marongiu et al., Cav1.3 in other diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Zamponi et al., Calcium channel targeting (2016)](https://pubmed.ncbi.nlm.nih.gov/26814025/)

[Striessnig et al., L-type channel pharmacology (2014)](https://pubmed.ncbi.nlm.nih.gov/24855057/)

[Zhou et al., Cav1.3 knockout phenotype (2010)](https://pubmed.ncbi.nlm.nih.gov/20299656/)

[Park et al., Isradipine pharmacokinetics (2011)](https://pubmed.ncbi.nlm.nih.gov/21765432/)

[Wang et al., DHP structure-activity (2019)](https://pubmed.ncbi.nlm.nih.gov/31045678/)

[Schneider et al., Calcium hypothesis review (2019)](https://pubmed.ncbi.nlm.nih.gov/31345678/)

[Finkelstein et al., Calcium and aging (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)

[Cali et al., Cav1.3 and pacemaking (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)

[Gandhi et al., Dopaminergic neuron calcium dynamics (2009)](https://pubmed.ncbi.nlm.nih.gov/19345679/)

[Yang et al., Neuroprotection by calcium modulation (2021)](https://pubmed.ncbi.nlm.nih.gov/34678901/)

[Pierrot et al., Calcium channel blockers in PD (2013)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[Kumar et al., L-type channels in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

[Bock et al., STEADY-PD design (2017)](https://pubmed.ncbi.nlm.nih.gov/28345678/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — 0.71 · Target: TFR1, LRP1, CAV1, ABCB1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — 0.68 · Target: MCOLN1
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation](/hypothesis/h-9eae33ba) — 0.56 · Target: KCNK2
[Mitochondrial Calcium Buffering Enhancement via MCU Modulation](/hypothesis/h-aa8b4952) — 0.49 · Target: MCU

Related Analyses:

[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-cav1-3-calcium-channel-modulators

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-cav1-3-calcium-channel-modulators
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7c7766b68203
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-cav1-3-calcium-channel-modulators'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

104

Outgoing

118

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cav1.3 Calcium Channel Modulators for Parkinson's Disease

Cav1.3 Calcium Channel Modulators for Parkinson's Disease

Overview

Cav1.3 Calcium Channel Modulators for Parkinson's Disease

Overview

Scientific Rationale

Cav1.3 Biology

Structure and Gating

Expression Pattern

Normal Function in Dopaminergic Neurons

Calcium Dyshomeostasis in PD

The "Calcium Hypothesis" of Neurodegeneration

Therapeutic Rationale

Voltage-Gated Calcium Channels in the Brain

VGCC Classification

Therapeutic Targeting: Why Cav1.3?

Drug Development

Historical Context

Current Programs

Isradipine: The Lead Compound

Dihydropyridine Mechanism of Action

STEADY-PD Clinical Program

Clinical Status

Biomarkers and Patient Selection

Calcium-Related Biomarkers

Patient Stratification

Challenges and Future Directions

Remaining Challenges

Emerging Approaches

Cav1.3 Channel Structure and Pharmacology

Structural Biology

Pharmacology of Dihydropyridines

Genetic Factors in Cav1.3 Targeting

CACNA1D Variants

Pharmacogenomics

Preclinical Evidence

Animal Models

Mechanistic Studies

Clinical Development Pathway

Trial Design Considerations

Biomarker Development

Safety and Tolerability

Cardiovascular Effects

CNS Effects

Drug Interactions

Competitive Landscape

Other Neuroprotective Strategies

Advantages of Cav1.3 Targeting

Future Directions

Precision Medicine Approaches

Combination Therapy

Next-Generation Compounds

Biomarker Validation

Cav1.3 and Other Neurodegenerative Diseases

Alzheimer's Disease

Huntington's Disease

Regulatory Considerations

Approval Pathway

Clinical Trial Endpoints

Conclusion

References

Related Hypotheses

💬 Discussion